Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer

被引：0
作者：
Samuel Murray
Vasilios Karavasilis
Mattheos Bobos
Evangelia Razis
Savvas Papadopoulos
Christos Christodoulou
Paris Kosmidis
George Fountzilas
机构：
[1] BioMarker Solutions Ltd,Department of Molecular Oncology
[2] GeneKOR,Department of Medical Oncology
[3] “Papageorgiou” Hospital,Department of Pathology
[4] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology
[5] Aristotle University of Thessaloniki School of Medicine,Department of Pathology
[6] “Hygeia” Hospital,Second Department of Medical Oncology
[7] “Hygeia” Hospital,Second Department of Medical Oncology
[8] “Metropolitan” Hospital,undefined
[9] “Hygeia” Hospital,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 31卷
关键词：
Predictive; Somatic mutation; EGFR; Gefitinib; Erlotinib; Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors
    Song Dong
    Xu-Chao Zhang
    Hua Cheng
    Jian-Quan Zhu
    Zhi-Hong Chen
    Yi-Fang Zhang
    Zhi Xie
    Yi-Long Wu
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 707 - 716
  • [42] Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
    Wu, Jenn-Yu
    Shih, Jin-Yuan
    ONCOTARGETS AND THERAPY, 2016, 9 : 6137 - 6145
  • [43] Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors
    T John
    G Liu
    M-S Tsao
    Oncogene, 2009, 28 : S14 - S23
  • [44] The role of EGFR tyrosine kinase inhibitors in the treatment of non-small cell lung cancer
    Kowalczyk, Anna
    Szutowicz-Zielinska, Ewa
    Dziadziuszko, Rafal
    Jassem, Jacek
    ONCOLOGY IN CLINICAL PRACTICE, 2005, 1 (04): : 217 - 224
  • [45] Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients
    Ruan, Yunfeng
    Jiang, Jie
    Guo, Liang
    Li, Yan
    Huang, Hailiang
    Shen, Lu
    Luan, Mengqi
    Li, Mo
    Du, Huihui
    Ma, Cheng
    He, Lin
    Zhang, Xiaoqing
    Qin, Shengying
    SCIENTIFIC REPORTS, 2016, 6
  • [46] Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer
    Rosell, R
    Ichinose, Y
    Taron, M
    Sarries, C
    Queralt, C
    Mendez, P
    Sanchez, JM
    Nishiyama, K
    Moran, T
    Cirauqui, B
    Mate, JL
    Besse, B
    Reguart, N
    Perez, M
    Sanchez, JJ
    LUNG CANCER, 2005, 50 (01) : 25 - 33
  • [47] Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer
    Tan, Fenlai
    Shi, Yuankai
    Wang, Yinxiang
    Ding, Lieming
    Yuan, Xiaobin
    Sun, Yan
    FUTURE ONCOLOGY, 2015, 11 (03) : 385 - 397
  • [48] EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
    van Zandwijk, N.
    Mathy, A.
    Boerrigter, L.
    Ruijter, H.
    Tielen, I.
    de Jong, D.
    Baas, P.
    Burgers, S.
    Nederlof, P.
    ANNALS OF ONCOLOGY, 2007, 18 (01) : 99 - 103
  • [49] Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer
    Gounant, Valerie
    Wislez, Marie
    Poulot, Virginie
    Khalil, Antoine
    Lavole, Armelle
    Cadranel, Jacques
    Milleron, Bernard
    LUNG CANCER, 2007, 58 (03) : 425 - 428
  • [50] Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors
    Zwitter, Matjaz
    Rossi, Antonio
    Di Maio, Massimo
    Perme, Maja Pohar
    Lopes, Gilberto
    RADIOLOGY AND ONCOLOGY, 2017, 51 (03) : 241 - 251
12345